Search results for "portion"

showing 10 items of 902 documents

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

2021

Not Available

OncologyMalechronic B cell leukemiachronic lymphocytic leukemia; ibrutinib; 4-factor score; prognosis.Datasets as TopicSeverity of Illness Indexchemistry.chemical_compoundPiperidinesRetrospective analysisMulticenter Studies as TopicChronicLeukemiaHematologyMiddle AgedPrognosisLymphocyticProgression-Free SurvivalIbrutinibFemalemedicine.medical_specialtyreal-word studyFactor scoreAntineoplastic AgentsAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival AnalysisRisk AssessmentNOibrutinibInternal medicineSeverity of illnessmedicineHumansProgression-free survivalProtein Kinase InhibitorsSurvival analysisAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelAdenineB-CellReproducibility of ResultsRetrospective cohort studyAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Survival Analysis; Severity of Illness IndexLeukemia Lymphocytic Chronic B-CellSurvival AnalysisSettore MED/15 - MALATTIE DEL SANGUEchemistrybusinesschronic lymphocytic leukaemiaFollow-Up Studies
researchProduct

Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort study.

2013

International audience; Multiple endocrine neoplasia syndrome type 1 (MEN1), which is secondary to mutation of the MEN1 gene, is a rare autosomal-dominant disease that predisposes mutation carriers to endocrine tumors. Although genotype-phenotype studies have so far failed to identify any statistical correlations, some families harbor recurrent tumor patterns. The function of MENIN is unclear, but has been described through the discovery of its interacting partners. Mutations in the interacting domains of MENIN functional partners have been shown to directly alter its regulation abilities. We report on a cohort of MEN1 patients from the Groupe d'étude des Tumeurs Endocrines. Patients with a…

OncologyMaleendocrine system diseasesProto-Oncogene Proteins c-jun[SDV]Life Sciences [q-bio]Diseasemedicine.disease_causeMESH: Protein Structure Tertiary0302 clinical medicineRisk FactorsMESH: Risk FactorsMESH : FemaleGenetics (clinical)MutationGeneral MedicineMESH: Follow-Up StudiesMESH : Risk Factors3. Good health030220 oncology & carcinogenesisCohortMESH : Proto-Oncogene ProteinsFemaleMESH : MutationMESH : Protein Structure TertiaryMESH : Proto-Oncogene Proteins c-junMESH : Multiple Endocrine Neoplasia Type 1Cohort studymedicine.medical_specialtyendocrine systemMESH: MutationGenetic counselingMESH : MaleMESH: Multiple Endocrine Neoplasia Type 1030209 endocrinology & metabolismBiology03 medical and health sciencesInternal medicineProto-Oncogene ProteinsGeneticsmedicineMultiple Endocrine Neoplasia Type 1HumansMEN1FamilyMolecular BiologyMESH: FamilyMESH: HumansMESH: Proto-Oncogene Proteins c-jun[ SDV ] Life Sciences [q-bio]Proportional hazards modelMESH : HumansCancerMESH : Follow-Up Studiesmedicine.diseaseMESH: MaleProtein Structure TertiaryMESH: Proto-Oncogene ProteinsMutationCancer researchMESH : FamilyMESH: FemaleFollow-Up Studies
researchProduct

Flexible statistical models provided new insights into the role of quantitative prognostic factors for mortality in gastric cancer.

2007

Abstract Objectives To reassess the effects of prognostic factors on mortality in gastric cancers, and to illustrate the advantages of flexible modeling. Study Design and Setting A prospective population-based cohort of persons diagnosed with gastric cancers in 1976 to 1995 in Burgundy, France, was followed for 5 years since diagnosis. Multivariable survival analyses, stratified by cancer stage, involved both conventional Cox's model and its flexible generalization, which permitted testing the underlying assumptions and accounting for changes over time in the effects of prognostic factors. Results Conventional assumptions of proportional hazards (PH) (P = 0.003) and linear increase in risk …

OncologyMalemedicine.medical_specialtyEpidemiologyPopulationStomach NeoplasmsInternal medicineEpidemiologymedicineHumansProspective StudieseducationStomach cancerProspective cohort studySurvival analysisAgedNeoplasm StagingProportional Hazards Modelseducation.field_of_studyModels Statisticalbusiness.industryProportional hazards modelAge FactorsCancerMiddle Agedmedicine.diseasePrognosisSurvival AnalysisCohortFemaleFrancebusinessDemographyJournal of clinical epidemiology
researchProduct

Prognostic significance of tumor ploidy and histomorphological parameters in adenocarcinoma of Barrett's esophagus.

1999

<i>Background:</i> Despite recent advances in surgical and multidisciplinary treatment, the prognosis for patients with adenocarcinoma of Barrett’s esophagus remains poor. The low prognostic accuracy of even surgical pathologic TNM staging suggests that additonal parameters are necessary in determining the prognosis. <i>Method:</i> In a retrospective analysis of 50 patients who underwent transhiatal or transthoracic esophageal resection due to adenocarcinoma of Barrett’s esophagus, a quantitative DNA analysis using image cytometry was performed in addition to the TNM classification and usual morphological criteria. At the time of DNA analysis the histomorphological p…

OncologyMalemedicine.medical_specialtyEsophageal NeoplasmsAdenocarcinomaGastroenterologyBarrett EsophagusEsophagusInternal medicinemedicineHumansEsophagusDna ploidyImage CytometryProportional Hazards ModelsRetrospective StudiesPloidiesProportional hazards modelbusiness.industryGastroenterologyRetrospective cohort studyDNA Neoplasmmedicine.diseasePrognosisdigestive system diseasesmedicine.anatomical_structureBarrett's esophagusAdenocarcinomaImage CytometrySurgeryFemalePloidybusinessDigestive surgery
researchProduct

Risk estimation for biliary tract cancer: Development and validation of a prognostic score.

2017

Background & Aims Biliary tract cancer is a rare tumour entity characterized by a poor prognosis. We aimed to identify prognostic factors and create a prognostic score to estimate survival. Methods Clinical data of the training set, consisting of 569 patients treated from 2000 to 2010 at Hannover Medical School, were analysed. A prognostic model defining three prognostic risk groups was derived from Cox regression analyses. The score was applied and validated in an independent cohort of 557 patients from four different German centres. Results Median overall survival (OS) was 14.5 months. If complete resection was performed, the patients had a significantly improved OS (23.9 months; n=242) a…

OncologyMalemedicine.medical_specialtyRisk AssessmentPrognostic scoreMetastasisCholangiocarcinomaCohort Studies03 medical and health sciences0302 clinical medicineInternal medicineGermanymedicineHumansAgedBiliary tract neoplasmBiliary tract cancerHepatologybusiness.industryProportional hazards modelMiddle Agedmedicine.diseasePrognosisSurgeryBiliary Tract Neoplasms030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyFemaleRisk assessmentbusinessCohort studyLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-…

2016

Objectives: To investigate cancer-specific mortality and other-cause mortality in prostate cancer patients with nodal metastases. Methods: The study included 411 patients treated with radical prostatectomy and pelvic lymph node dissection for prostate cancer with lymph node metastases at 10 tertiary care centers between 1995 and 2014. Kaplan–Meier analyses were used to assess cancer-specific mortality-free survival rates at 8 years' follow up in the overall population, and after stratifying patients according to clinical and pathological parameters. Uni- and multivariable competing risk Cox regression analyses were used to assess cancer-specific mortality and other-cause mortality. Finally,…

OncologyMalemedicine.medical_treatment030232 urology & nephrologyProstate cancer0302 clinical medicineRobotic Surgical ProceduresLymph nodeeducation.field_of_studyProstatectomyMortality rateLymph NodePrognosiscancer-specific mortality competing risk analysis lymph node metastases other-cause mortality radical prostatectomylymph node metastaseDissectionmedicine.anatomical_structure030220 oncology & carcinogenesisLymphatic MetastasisLymphSurvival Analysicancer-specific mortality; competing risk analysis; lymph node metastases; other-cause mortality; radical prostatectomycancer-specific mortality; competing risk analysis; lymph node metastases; other-cause mortality; radical prostatectomy; Urologyother-cause mortalityHumanlymph node metastasesRiskmedicine.medical_specialtyRobotic Surgical ProcedurePrognosiUrologyPopulationUrologycancer-specific mortality03 medical and health sciencesInternal medicinemedicineHumanseducationcompeting risk analysiProstatectomybusiness.industryProportional hazards modelcompeting risk analysisProstatic NeoplasmsLymphatic MetastasiProstate-Specific Antigenmedicine.diseaseSurvival Analysisradical prostatectomyProstatic NeoplasmLymph Node ExcisionLaparoscopyLymph Nodesbusiness
researchProduct

Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes

2020

Interferons are crucial for adaptive immunity and play an important role in the immune landscape of breast cancer. Using microarray-based gene expression analysis, we examined the subtype-specific prognostic significance of interferon-&gamma

OncologyMicroarrayReceptor ErbB-2animal diseasesKaplan-Meier Estimatelcsh:ChemistryMedicinelcsh:QH301-705.5Spectroscopymolecular subtypesHazard ratioGeneral MedicineinterferonMiddle AgedAcquired immune systemProgression-Free SurvivalComputer Science ApplicationsGene Expression Regulation NeoplasticReceptors EstrogenCohortFemaleReceptors ProgesteroneSignal Transductionmedicine.medical_specialtyBreast Neoplasmschemical and pharmacologic phenomenaDisease-Free SurvivalArticleCatalysisInorganic ChemistryInterferon-gammaBreast cancerImmune systembreast cancerInternal medicineBiomarkers TumorHumansPhysical and Theoretical ChemistryMolecular BiologyAgedNeoplasm Stagingbusiness.industryProportional hazards modelOrganic Chemistrybreast cancer ; prognosis ; interferon ; molecular subtypesbiochemical phenomena metabolism and nutritionGene signaturemedicine.diseaselcsh:Biology (General)lcsh:QD1-999bacteriaprognosisbusinessInternational Journal of Molecular Sciences
researchProduct

Multivariate independent prognostic factors in endometrial carcinoma: A clinicopathologic study in 181 patients

2003

The aim of this study was to evaluate the biologic outcome of endometrial carcinomas as compared to clinical and pathologic parameters and to identify multivariate independent prognostic factors. Charts were abstracted from patients with endometrial carcinoma from 1985 to 1995. Data on clinicopathologic variables, adjuvant treatment, site of recurrence, and survival were collected. χ2 test was used to test association between variables. Kaplan-Maier method was used for survival analysis and Cox proportional hazards model for multiple regression analysis. Univariate analysis revealed that FIGO stage, tumor grade, depth of myometrial invasion, biochemical analysis of progesterone receptor sta…

OncologyMultivariate statisticsUnivariate analysismedicine.medical_specialtyMultivariate analysisbusiness.industryProportional hazards modelObstetrics and GynecologyProgesterone Receptor Statusmedicine.diseaseOncologyInternal medicineCarcinomamedicineStage (cooking)businessSurvival analysisInternational Journal of Gynecologic Cancer
researchProduct

Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic …

2015

Abstract Purpose: We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective–retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials.gov, NCT0039183). Experimental Design: Outcomes were from the study's primary analysis. RAS mutations beyond KRAS exon 2 (KRAS exons 3, 4; NRAS exons 2, 3, 4; BRAF exon 15) were detected by bidirectional Sanger sequencing in wild-type KRAS exon 2 tumor specimens. Progression-free survival (PFS) and overall survival (OS) we…

OncologyNeuroblastoma RAS viral oncogene homologAdultMaleProto-Oncogene Proteins B-rafCancer Researchmedicine.medical_specialtyColorectal cancerPopulationDNA Mutational AnalysisLeucovorinmedicine.disease_causeInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicinePanitumumabHumansNeoplasm MetastasiseducationAgedProportional Hazards ModelsAged 80 and overeducation.field_of_studybusiness.industryPanitumumabCancerAntibodies MonoclonalExonsMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesIrinotecanGenes rasTreatment OutcomeOncologyMutationRetreatmentFOLFIRICamptothecinFemaleKRASFluorouracilHuman medicinebusinessColorectal Neoplasmsmedicine.drugClinical cancer research
researchProduct

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of r…

2015

BackgroundAcquired resistance to BRAF inhibitors (BRAFi) is a near-universal phenomenon caused by numerous genetic and non-genetic alterations. In this study, we evaluated the spectrum, onset, pattern of progression, and subsequent clinical outcomes associated with specific mechanisms of resistance.MethodsWe compiled clinical and genetic data from 100 patients with 132 tissue samples obtained at progression on BRAFi therapy from 3 large, previously published studies of BRAFi resistance. These samples were subjected to whole-exome sequencing and/or polymerase chain reaction-based genetic testing.ResultsAmong 132 samples, putative resistance mechanisms were identified in 58%, including NRAS o…

OncologyNeuroblastoma RAS viral oncogene homologMaleCancer ResearchSkin NeoplasmsTime FactorsResistanceDNA Mutational AnalysisDrug ResistanceMedizinKaplan-Meier EstimateBioinformaticsmedicine.disease_causeRisk Factors2.1 Biological and endogenous factorsAetiologyVemurafenibMelanomaCancerMutationTumorDabrafenibMelanomaAcquiredMiddle AgedPhenotypeEuropePhenotypeTreatment OutcomeSpliceOncologyMeta-analysisPublic Health and Health ServicesDisease ProgressionFemalemedicine.drugSignal TransductionProto-Oncogene Proteins B-rafmedicine.medical_specialtyOncology and CarcinogenesisNRASAntineoplastic AgentsBiologyDisease-Free SurvivalArticleBRAFMEK1Clinical ResearchInternal medicineGeneticsmedicineBiomarkers TumorHumansGenetic Predisposition to DiseaseOncology & CarcinogenesisProtein Kinase InhibitorsProportional Hazards ModelsProportional hazards modelAustraliaDabrafenibmedicine.diseaseMAPKUnited StatesMeta-analysisVemurafenibDrug Resistance NeoplasmMutationNeoplasmBiomarkersEuropean journal of cancer (Oxford, England : 1990)
researchProduct